Compare Sana Biotechnology Inc (SANA) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wynn Resorts, Limited — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Wynn Resorts, Limited trades at $94.75 (market cap $9.93B). The key difference: Wynn Resorts, Limited is far larger — about 11.4× Sana Biotechnology Inc's market cap, and Wynn Resorts, Limited pays a 1.05% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | WYNN | |
|---|---|---|
Market Cap | $873.84M | $9.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $133.34 |
52-Week Low | $2.68 | $94.78 |
Enterprise Value | $848.03M | $20.29B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Wynn Resorts (WYNN) trades at $94.63, down 2.08% today, amid a bearish technical signal with recent earnings misses. The company maintains strong revenue growth with $7.14B in 2025, though net margins have compressed to 4.58%. Recent news highlights operational awards and Q2 2026 earnings anticipation. Technical indicators show support near $93-$95 with resistance at $97-$99, while RSI levels suggest neutral momentum.
Outlook remains mixed: analyst consensus is bullish with a $135.50 price target (64% buy ratings), but high debt ($10.5B long-term) and margin pressure pose risks. The stock offers potential upside if Macau and Las Vegas momentum sustains, though geopolitical and competitive headwinds require monitoring. Near-term catalysts include Q2 earnings on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
